Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

K. Sarafoglou, C. N. Barnes, M. Huang, E. A. Imel, I. Madu, D. P. Merke, D. Moriarty, S. Nakhle, R. S. Newfield, M. G. Vogiatzi, R. J. Auchus

Research output: Contribution to journalComment/debatepeer-review

Abstract

Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200 mg QD. The correct dose is 200 mg BID.

Original languageEnglish (US)
Pages (from-to)E3546
JournalJournal of Clinical Endocrinology and Metabolism
Volume107
Issue number8
DOIs
StatePublished - Aug 1 2022

Bibliographical note

Publisher Copyright:
© 2022 Endocrine Society. All rights reserved.

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies'. Together they form a unique fingerprint.

Cite this